The Refund Covered One Bottle, Not Years of Markups
Compare Cosequin chew costs with bulk MSM, review the retired mobility claims, and check the closed claim window and unresolved payment status.
Nutramax’s proposed $11.5 million Cosequin settlement offered up to $25 per qualifying product and $150 per household—roughly the cost of one bottle for many buyers—while requiring three mobility claims to be discontinued. The bargain looks less favorable when judged per gram: the refund addressed no more than six units, but buyers paid the branded-chew premium on every bottle. That is a price argument, not a court finding that Cosequin, MSM, glucosamine, or chondroitin does not work.
The ordinary claim window is closed. The official settlement website says claims were due July 21, 2026. The records reviewed do not establish final approval, settlement finality, an appeal outcome, a payment date, or payment issuance.
The Best Case For Paying The Brand Premium
The received wisdom is reasonable: a veterinarian-recommended brand may be worth more than commodity powder because the buyer is paying for formulation, palatability, convenient dosing, manufacturing controls, and confidence that a dog will actually consume the product. A chew combining several ingredients is not identical to a bag of plain MSM, and sticker price alone cannot establish equivalent quality or clinical effect.
The settlement does not erase those differences. Nutramax denied wrongdoing and liability, and the court-authorized notice said the court had made no determination of wrongdoing. A negotiated settlement is not a scientific verdict against Cosequin or any ingredient.
The litigation cited research in which glucosamine-supplemented dogs showed “no significant improvement compared with dogs receiving placebo,” according to the ClassAction.org investigation page. That does not prove every formulation is ineffective for every dog. It does show why broad mobility language needs evidence specific to the claimed outcome.
The consensus is therefore right in a limited sense: quality assurance, convenience, flavoring, and a multi-ingredient format can justify some premium. The settlement matters because three more specific promotional claims were part of what distinguished the branded product, and those claims are contractually slated for retirement under the proposed resolution. Once those promises are removed, the remaining premium deserves a direct cost audit.
The Per-Gram Audit Exposes The Markup
Plain US-made OptiMSM was listed at $34.28 per pound, or approximately $0.076 per gram. By comparison, branded chews deliver label quantities measured in hundreds of milligrams per chew, often at a multi-dollar serving cost. Exact Cosequin label amounts and current bottle prices vary by formulation and retailer, so there is no honest single ratio for all seven covered products.
The calculator below uses the brief’s representative default: a $30, 60-count bottle and editable label quantities. Those default label quantities are an illustrative scenario, not a claim about every covered Cosequin product. Enter the numbers from the package you are considering. The tool calculates monthly chew cost, cost per gram of labeled glucosamine, chondroitin and MSM combined, and the ingredient-equivalent cost of the MSM portion at the cited bulk baseline.
Enter your bottle’s label and your dog’s daily serving; the result identifies which option costs less for those inputs.
Use the package price, count, labeled actives and your dog’s daily serving. Defaults model a ~$30, 60-count combination chew bottle.
Weight is recorded for your comparison; use the label or veterinarian’s serving rather than deriving a dose from weight here.
The ingredient defaults are an illustrative scenario, not the label of every covered product. Replace them with your package values.
The chews cost $30.00 per 30 days and $0.42 per gram of labeled actives. Their 30-day MSM quantity costs ~$0.91 at the plain-powder baseline, a ~$29.09 difference.
| Measure | Per Day | 30 Days | Cost |
|---|---|---|---|
| Combination chews | 2 chews | 60 chews | $30.00 |
| Glucosamine | 1.20 g | 36.00 g | — |
| Chondroitin | 0.40 g | 12.00 g | — |
| MSM in chews | 0.80 g | 24.00 g | Included |
| Same MSM as plain powder | 0.80 g | 24.00 g | ~$0.91 |
| All labeled actives | 2.40 g | 72.00 g | $0.42/g |
Cost comparison only: plain MSM is not clinically equivalent to a combination chew and does not include glucosamine, chondroitin, flavoring, formulation, testing or veterinary care.
Source: settlement figures and covered-claim terms from the official Cosequin settlement materials and ConsumerLab; plain OptiMSM baseline ~$0.076/g from $34.28/lb. Default bottle and label values are an illustrative scenario from the article brief.
This is not a clinical-equivalence calculator. Plain MSM does not replace glucosamine, chondroitin, flavoring, formulation work, or veterinary guidance. The comparison isolates what can be measured from a label: dollars per gram of listed actives and the cost of the MSM quantity at a plain-powder price.
The distinction is especially important where a chew contains all three ingredients. Total-actives cost gives the branded product credit for every labeled milligram of glucosamine, chondroitin, and MSM. The MSM-only comparison asks a narrower question: how much would the same labeled mass of MSM cost at approximately $0.076 per gram? Neither calculation proves equal absorption, purity, adherence, or clinical outcome.
The Settlement Retires Three Specific Mobility Claims
Under the proposed settlement, Nutramax agreed to discontinue three statements in future advertising or packaging for qualifying canine products:
- “Mobility, Cartilage and Joint Health Support”
- “Supports Mobility for a Healthy Lifestyle”
- “Use Cosequin to help your pet Climb stairs, Rise and Jump!”
ConsumerLab’s settlement report identifies the $11.5 million fund, the three statements, and the seven covered formulations. A more general phrase, “Joint Health Supplement,” could remain, according to a separate legal-news account.
That is a narrow change, not a ban on the brand or on joint-supplement language. It also is not an admission that the products are ineffective. Nutramax denied the allegations, and settlement avoids the expense and uncertainty of continued litigation.
Still, the wording matters to a price analysis. “Climb stairs, Rise and Jump” describes observable function, not merely the presence of ingredients in a chew. “Supports Mobility for a Healthy Lifestyle” similarly gives the buyer a reason to expect more than convenient delivery. If those claims helped support a premium, their negotiated removal weakens the case for paying that premium without separately examining formulation quality and evidence.
Implementation and enforceability remain tied to approval and finality. The records supplied for this review do not confirm that every required change has appeared on every package, retailer page, advertisement, or distribution channel.
One Refund Did Not Repay The Recurring Premium
The proposed benefit was up to $25 per qualifying unit, for no more than six units and no more than $150 per household. Payments could be reduced proportionally if valid claims exceeded the net amount available after approved deductions.
| Approved Units | Maximum Benefit |
|---|---|
| 1 | $25 |
| 2 | $50 |
| 3 | $75 |
| 4 | $100 |
| 5 | $125 |
| 6 or more | $150 |
The $11.5 million headline was a gross fund, not money reserved entirely for purchasers. It was also intended to cover court-approved attorneys’ fees and expenses, service awards for class representatives, and valid consumer claims. The records reviewed do not establish the net consumer pool or whether a pro rata reduction was ultimately applied.
The economic mismatch is straightforward. A qualifying buyer could claim up to $25 for one unit, but the brand premium was embedded in each prior purchase. Even the $150 household ceiling stopped at six units and combined everyone at the same physical address. It was not $150 for each purchaser.
This does not make the formula unlawful or inadequate; the court process addresses settlement fairness. It does mean the consumer benefit should not be mistaken for reimbursement of years of price premiums. At most, the published formula compensated six qualifying units, subject to deductions, claim validity, and possible reduction.
Only Seven California Products Were Covered
The settlement class was limited to qualifying California purchasers who bought specified products from May 3, 2016 through May 6, 2022 for personal or household use, not resale or another business purpose. Only one claim form was permitted per physical-address household.
| Form | Covered Product |
|---|---|
| Tablet | Cosequin DS Maximum Strength Chewable Tablets |
| Tablet | Cosequin DS Maximum Strength Plus MSM Chewable Tablets |
| Tablet | Cosequin Maximum Strength Plus MSM Chewable Tablets |
| Tablet | Cosequin with MSM Chewable Tablets |
| Soft chew | Cosequin DS Maximum Strength Plus MSM Soft Chews |
| Soft chew | Cosequin Maximum Strength Plus MSM Soft Chews |
| Soft chew | Cosequin with MSM Soft Chews |
Six names include MSM; Cosequin DS Maximum Strength Chewable Tablets is the exception. “Cosequin MSM settlement” is therefore useful search language, but it is not the legal class definition. An unrelated MSM product, an unlisted Cosequin formulation, a business purchase, or a purchase outside the stated dates did not qualify.
Exact product names mattered. A similarly named powder, capsule, tablet, or soft chew was not covered unless it matched one of the seven specified formulations. Meeting the class definition also did not guarantee payment: a claimant needed a timely, valid claim subject to administrator review.
The Deadline Passed, But Payment Status Remains Unclear
The case is Lytle and Musthaler v. Nutramax Laboratories, Inc. and Nutramax Laboratories Veterinary Sciences, Inc., No. 5:19-cv-00835, in the U.S. District Court for the Central District of California. The principal dates in the available record are:
| Date | Event |
|---|---|
| May 3, 2016–May 6, 2022 | Covered purchases |
| February 2, 2026 | Reported preliminary approval |
| June 22, 2026 | Exclusion and objection deadline |
| July 21, 2026 | Claim deadline |
| August 13, 2026, 10:00 a.m. | Scheduled fairness hearing |
The official FAQ describes the proposed fund and class terms. A ClassAction.org settlement report reports preliminary approval on February 2, 2026 and says payment depended on final approval and resolution of appeals.
A scheduled hearing is not proof of what the judge decided. The supplied records do not establish a post-hearing final-approval order, judgment, appeal status, effective date, distribution announcement, or payment issuance. The defensible current status is narrower: the claim deadline passed; the later procedural and payment status is not established here.
People who filed should use CosequinCASettlement.com or call the listed administrator number, 888-899-7783. Keep the claim-confirmation number, addresses used, filing date, receipts, order histories, product photographs, and administrator correspondence. The reviewed records do not establish a public claim-status tool or a generally available procedure for late claims, corrections, rejected claims, changed payment details, or replacement payments.
People who missed July 21 should not assume a late claim will be accepted. Questions about personal legal rights, released claims, tolling, or separate litigation require advice from a qualified attorney rather than an unofficial settlement directory.
The Settlement Does Not Decide Whether MSM Works
Six covered products named MSM, but the case was not a general action against MSM. It concerned alleged misrepresentations in advertising and packaging for seven specified canine Cosequin supplements.
The settlement does not establish that Cosequin, MSM, glucosamine, chondroitin, or canine joint supplements are effective or ineffective. Nor does negotiated removal of a statement prove that no individual dog benefits. Clinical efficacy depends on evidence beyond settlement documents, and a veterinarian should guide care for pain, impaired mobility, or a suspected joint condition.
The price conclusion is firmer and narrower. Bulk MSM’s cited baseline is approximately $0.076 per gram. A branded combination chew can cost much more per gram of labeled actives, although the exact multiple depends on its price, count, label amounts, and dose. Buyers may rationally pay extra for quality controls, convenience, palatability, or other ingredients. They should no longer treat the three retired mobility statements as the automatic justification for that premium.
The Practical Verdict For The Next Bottle
For a new purchase, ignore the expired refund when comparing options. It addressed at most six historical units and is not documented as available to new claimants. Compare the current bottle on four measurable terms: price, chew count, label milligrams, and the daily serving for the dog.
Then separate the measurable premium from the unmeasured benefits. The calculator gives the chew full credit for all three labeled actives while showing the much lower ingredient cost of its MSM portion at the cited bulk price. It cannot price testing standards, flavor, convenience, or trust because the draft record supplies no figures for them.
That is the settlement’s useful purchasing lesson. The proposed fund offered approximately one bottle’s price per approved unit, while the markup recurred with every bottle. Three outcome-oriented mobility claims are slated to disappear. Any remaining premium now has to stand on disclosed actives, verifiable quality, convenience, and evidence—not on the retired promises.